Edition:
India

Ultragenyx Pharmaceutical Inc (RARE.OQ)

RARE.OQ on NASDAQ Stock Exchange Global Select Market

53.39USD
22 Jan 2018
Change (% chg)

-- (--)
Prev Close
$53.39
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
172,699
52-wk High
$91.17
52-wk Low
$43.14

Select another date:

BRIEF-Ultragenyx Announces Proposed Public Offering Of Common Stock

* ULTRAGENYX ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Capital International Investors Reports 10.3 Pct Passive Stake In Ultragenyx

* CAPITAL INTERNATIONAL INVESTORS REPORTS 10.3 PERCENT PASSIVE STAKE IN ULTRAGENYX PHARMACEUTICAL INC AS OF DECEMBER 29, 2017 - SEC FILING‍​ Source text for Eikon: (http://bit.ly/2D1HymY) Further company coverage:

BRIEF-Ultragenyx Announces Update To UX007 Development Program In Long-Chain Fatty Acid Oxidation Disorder Patients

* ULTRAGENYX ANNOUNCES UPDATE TO UX007 DEVELOPMENT PROGRAM IN LONG-CHAIN FATTY ACID OXIDATION DISORDER PATIENTS

BRIEF-Ultragenyx Sells Priority Review Voucher For $130 Mln

* ENTERED INTO A DEFINITIVE AGREEMENT TO SELL ITS RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER TO NOVARTIS Source text for Eikon: Further company coverage:

BRIEF-Ultragenyx And Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion For Treatment Of X-Linked Hypophosphatemia In Children

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE BUROSUMAB RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF X-LINKED HYPOPHOSPHATEMIA IN CHILDREN

BRIEF-Ultragenyx And Kyowa Kirin Announce Positive 48-Week Data From Adult Phase 3 Study Of Burosumab In X-Linked Hypophosphatemia

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE POSITIVE 48-WEEK DATA FROM ADULT PHASE 3 STUDY OF BUROSUMAB (KRN23) IN X-LINKED HYPOPHOSPHATEMIA Source text for Eikon: Further company coverage:

BRIEF-Ultragenyx completes patients dosing in first cohort of phase 1/2 study of DTX301

* Ultragenyx announces completion of patient dosing in first cohort of phase 1/2 clinical study of dtx301 gene therapy in ornithine transcarbamylase (OTC) deficiency

BRIEF-ULTRAGENYX SAYS FDA APPROVES MEPSEVII FOR GENETIC DISEASE MUCOPOLYSACCHARIDOSIS VII

* ULTRAGENYX ANNOUNCES FDA APPROVAL OF MEPSEVII™ (VESTRONIDASE ALFA), THE FIRST THERAPY FOR PROGRESSIVE AND DEBILITATING RARE GENETIC DISEASE MUCOPOLYSACCHARIDOSIS VII

FDA approves Ultragenyx drug for rare enzyme disorder

The U.S. Food and Drug Administration approved on Wednesday a new treatment made by Ultragenyx Pharmaceutical Inc for a rare genetic disorder that can dramatically reduce life expectancy.

UPDATE 1-U.S. FDA approves Ultragenyx drug for rare enzyme disorder

Nov 15 The U.S. Food and Drug Administration approved on Wednesday a new treatment made by Ultragenyx Pharmaceutical Inc for a rare genetic disorder that can dramatically reduce life expectancy.

Select another date: